Russian Scientists Create First Theranostic Pair To Diagnose And Treat Prostate Cancer

Researchers at Tomsk Polytechnic University have made a groundbreaking advancement in the fight against prostate cancer, creating and securing a patent for Russia's inaugural theranostic pair.

This innovative development consists of novel radiopharmaceuticals that serve dual purposes: diagnosing and treating the disease. This achievement marks a significant milestone as it represents Russia's entry into the field of theranostics, which combines therapeutic and diagnostic processes into one treatment for cancer.

Roman Zelchan, senior researcher at the Oncoteranostics Research Centre of TPU's Research School of Chemical and Biomedical Technologies, shared his enthusiasm for the project's success. He also holds a position as the leading research associate at the Department of Radionuclide Therapy and Diagnostics within the Tomsk Research Institute of Oncology. Zelchan remarked, "We can safely say that Tomsk Polytechnic University has developed the first domestic theranostic pair."

In tackling prostate cancer, which ranks as the second most frequently diagnosed cancer among men globally, affecting about one in eight men during their lifetime, the TPU team's work presents a significant leap forward. The newly developed radiopharmaceuticals utilize the BQ—PSMA compound, laying the foundation for creating both diagnostic and therapeutic agents.

This compound becomes particularly effective when linked with the diagnostic radioactive isotope technetium-99m, which functions akin to a "signal beacon" to pinpoint tumor cells. Further enhancing its potency, the addition of the therapeutic isotope lutetium-177 targets and combats tumor cells more aggressively.

This development is a notable achievement in global cancer research. Before this, the theranostic field recognized only two molecules worldwide dedicated to the diagnosis and treatment of neuroendocrine tumors and prostate cancer, both of which were the fruits of international efforts.

Hence, TPU's success in developing a theranostic pair propels Russia to the forefront of innovative cancer treatment, showcasing its capabilities in merging diagnostic and therapeutic methodologies for more effective cancer care.

The initial phase of pilot clinical trials has yielded positive outcomes, signaling a promising future for this theranostic pair in clinical settings. The TPU press service has heralded these results, indicating a successful first step towards a broader application of these radiopharmaceuticals in treating prostate cancer patients. This achievement not only advances cancer treatment but also positions Russian scientists as leaders in the emerging field of theranostics.

As clinical trials continue to show promising results, the potential for these radiopharmaceuticals to improve patient outcomes and contribute to the broader field of cancer treatment continues to grow.